SAB Biotherapeutics (NASDAQ:SABS) Rating Increased to Strong-Buy at Jefferies Financial Group

Posted by Francis Steltz on May 21st, 2026

Jefferies Financial Group upgraded shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, May 11th. HC Wainwright increased their price objective on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Chardan Capital increased their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.00.

View Our Latest Report on SABS

SAB Biotherapeutics Price Performance

SABS stock opened at $3.68 on Wednesday. The stock has a market capitalization of $187.50 million, a PE ratio of -1.74 and a beta of 0.55. The company’s 50-day moving average is $3.85 and its 200-day moving average is $3.84. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics has a 1 year low of $1.60 and a 1 year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Equities research analysts expect that SAB Biotherapeutics will post -1.19 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its holdings in shares of SAB Biotherapeutics by 424.8% in the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock worth $213,000 after acquiring an additional 45,084 shares during the last quarter. Stempoint Capital LP raised its holdings in shares of SAB Biotherapeutics by 155.9% in the 1st quarter. Stempoint Capital LP now owns 375,000 shares of the company’s stock worth $1,436,000 after acquiring an additional 228,442 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of SAB Biotherapeutics in the 1st quarter worth about $2,202,000. Monashee Investment Management LLC acquired a new stake in shares of SAB Biotherapeutics in the 1st quarter worth about $1,915,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics in the 1st quarter worth about $29,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics News Roundup

Here are the key news stories impacting SAB Biotherapeutics this week:

Positive Sentiment: Jefferies initiated coverage of SAB Biotherapeutics with a Buy rating, a bullish signal that may be encouraging traders to revalue the stock higher. Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation
Neutral Sentiment: Brookline Capital Markets released updated earnings estimates across 2026-2030, projecting continued losses in the near term but a path to profitability by FY2030. These forecasts provide a longer-term valuation framework, but they do not appear to be a major immediate catalyst. SAB Biotherapeutics Inc SABS
Negative Sentiment: The company’s most recent quarterly results missed analyst expectations, with EPS of -$0.35 versus consensus of -$0.20, reinforcing concerns about near-term execution and profitability. SAB Biotherapeutics Inc SABS

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.